Stay updated on Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page.

Latest updates to the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedAdded the term Hepatocellular carcinoma and a new 'Genetic and Rare Diseases Information Center' resource; updated the site revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check46 days agoChange DetectedPage version updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check68 days agoChange DetectedThe study now lists two locations, including Parkland Health & Hospital System in Dallas, TX; this augments the previously listed single-location site.SummaryDifference0.4%

- Check75 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding status notice and the previous Revision: v3.4.1 from the page.SummaryDifference0.4%

- Check82 days agoChange DetectedPage now shows a government funding lapse notice with the NIH Clinical Center's operating status. The revision label has been updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page.